483 related articles for article (PubMed ID: 30128536)
21. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C;
Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633
[TBL] [Abstract][Full Text] [Related]
22. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer.
Lin PH; Kuo WH; Huang AC; Lu YS; Lin CH; Kuo SH; Wang MY; Liu CY; Cheng FT; Yeh MH; Li HY; Yang YH; Hsu YH; Fan SC; Li LY; Yu SL; Chang KJ; Chen PL; Ni YH; Huang CS
Oncotarget; 2016 Feb; 7(7):8310-20. PubMed ID: 26824983
[TBL] [Abstract][Full Text] [Related]
23. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract][Full Text] [Related]
24. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
25. New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
Gervas P; Molokov A; Ivanova A; Panferova Y; Kiselev A; Chernyshova A; Pisareva L; Choynzonov E; Cherdyntseva N
Exp Oncol; 2021 Mar; 43(1):52-55. PubMed ID: 33785725
[TBL] [Abstract][Full Text] [Related]
26. Inherited Mutations in Women With Ovarian Carcinoma.
Norquist BM; Harrell MI; Brady MF; Walsh T; Lee MK; Gulsuner S; Bernards SS; Casadei S; Yi Q; Burger RA; Chan JK; Davidson SA; Mannel RS; DiSilvestro PA; Lankes HA; Ramirez NC; King MC; Swisher EM; Birrer MJ
JAMA Oncol; 2016 Apr; 2(4):482-90. PubMed ID: 26720728
[TBL] [Abstract][Full Text] [Related]
27. The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort.
Hu C; Polley EC; Yadav S; Lilyquist J; Shimelis H; Na J; Hart SN; Goldgar DE; Shah S; Pesaran T; Dolinsky JS; LaDuca H; Couch FJ
J Natl Cancer Inst; 2020 Dec; 112(12):1231-1241. PubMed ID: 32091585
[TBL] [Abstract][Full Text] [Related]
28. Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer.
Felicio PS; Grasel RS; Campacci N; de Paula AE; Galvão HCR; Torrezan GT; Sabato CS; Fernandes GC; Souza CP; Michelli RD; Andrade CE; Barros BDF; Matsushita MM; Revil T; Ragoussis J; Couch FJ; Hart SN; Reis RM; Melendez ME; Tonin PN; Carraro DM; Palmero EI
Hum Mutat; 2021 Mar; 42(3):290-299. PubMed ID: 33326660
[TBL] [Abstract][Full Text] [Related]
29. Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families.
Castéra L; Harter V; Muller E; Krieger S; Goardon N; Ricou A; Rousselin A; Paimparay G; Legros A; Bruet O; Quesnelle C; Domin F; San C; Brault B; Fouillet R; Abadie C; Béra O; Berthet P; ; Frébourg T; Vaur D
Genet Med; 2018 Dec; 20(12):1677-1686. PubMed ID: 29988077
[TBL] [Abstract][Full Text] [Related]
30. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
31. UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes:
Hanson H; Kulkarni A; Loong L; Kavanaugh G; Torr B; Allen S; Ahmed M; Antoniou AC; Cleaver R; Dabir T; Evans DG; Golightly E; Jewell R; Kohut K; Manchanda R; Murray A; Murray J; Ong KR; Rosenthal AN; Woodward ER; Eccles DM; Turnbull C; Tischkowitz M; ; Lalloo F
J Med Genet; 2023 May; 60(5):417-429. PubMed ID: 36411032
[TBL] [Abstract][Full Text] [Related]
32. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
da Costa E Silva Carvalho S; Cury NM; Brotto DB; de Araujo LF; Rosa RCA; Texeira LA; Plaça JR; Marques AA; Peronni KC; Ruy PC; Molfetta GA; Moriguti JC; Carraro DM; Palmero EI; Ashton-Prolla P; de Faria Ferraz VE; Silva WA
BMC Med Genomics; 2020 Feb; 13(1):21. PubMed ID: 32039725
[TBL] [Abstract][Full Text] [Related]
33. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women.
Kurian AW; Hughes E; Handorf EA; Gutin A; Allen B; Hartman AR; Hall MJ
JCO Precis Oncol; 2017 Nov; 1():1-12. PubMed ID: 35172496
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women.
Zeng C; Guo X; Wen W; Shi J; Long J; Cai Q; Shu XO; Xiang Y; Zheng W
Breast Cancer Res Treat; 2020 Jun; 181(2):465-473. PubMed ID: 32318955
[TBL] [Abstract][Full Text] [Related]
35. Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women.
Sepahi I; Faust U; Sturm M; Bosse K; Kehrer M; Heinrich T; Grundman-Hauser K; Bauer P; Ossowski S; Susak H; Varon R; Schröck E; Niederacher D; Auber B; Sutter C; Arnold N; Hahnen E; Dworniczak B; Wang-Gorke S; Gehrig A; Weber BHF; Engel C; Lemke JR; Hartkopf A; Nguyen HP; Riess O; Schroeder C
BMC Cancer; 2019 Aug; 19(1):787. PubMed ID: 31395037
[TBL] [Abstract][Full Text] [Related]
36. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
Nurmi A; Muranen TA; Pelttari LM; Kiiski JI; Heikkinen T; Lehto S; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Nevanlinna H
Int J Cancer; 2019 Nov; 145(10):2692-2700. PubMed ID: 30927251
[TBL] [Abstract][Full Text] [Related]
37. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
38. Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
Shahi RB; De Brakeleer S; Caljon B; Pauwels I; Bonduelle M; Joris S; Fontaine C; Vanhoeij M; Van Dooren S; Teugels E; De Grève J
BMC Cancer; 2019 Apr; 19(1):313. PubMed ID: 30947698
[TBL] [Abstract][Full Text] [Related]
39. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution's high-risk population.
Meiss AE; Thomas M; Modesitt SC; Ring KL; Atkins KA; Mills AM
Hum Pathol; 2018 Dec; 82():20-31. PubMed ID: 29958926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
